It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.

doi:10.1111/trf.12941

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.

Transfusion - 1 Mar 2015

Sandler S Gerald, Flegel Willy A, Westhoff Connie M, Denomme Gregory A, Delaney Meghan, Keller Margaret A, Johnson Susan T, Katz Louis, Queenan John T, Vassallo Ralph R, Simon Clayton D

Abstract excerpt

No abstract is available from the source.

Topics

Amino Acid Substitution
Antibodies, Monoclonal
Antigen-Antibody Reactions
Blood Group Incompatibility
Blood Grouping and Crossmatching
Epitopes
Erythroblastosis, Fetal
False Negative Reactions
Female
Genotype
Genotyping Techniques
Hemagglutination Tests

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Humans

Infant, Newborn

Isoantibodies

Male

Phenotype

Pregnancy

Source

Open in PubMed Open full text

Identifiers

PMID: 25438646
DOI: 10.1111/trf.12941
PMCID: PMC4357540

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.PMID 25438646Read ↗

It's time to phase out "serologic weak D phenotype" and resolve D types with RHD genotyping including weak D type 4.Semantic proximity Read ↗

Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the Comprehensive Transfusion Medicine survey of the College of American Pathologists.Semantic proximity Read ↗

[Importance of molecular RhD genotyping in transfusion medicine].Semantic proximity Read ↗

Impact of RHD genotyping on transfusion practice in Denmark and the United States and identification of novel RHD alleles.Semantic proximity Read ↗

Rh Immunoprophylaxis for Women With a Serologic Weak D Phenotype.Semantic proximity Read ↗

Transfusion support for a woman with RHD*09.01.02 and the novel RHD*01W.161 allele in trans.Semantic proximity Read ↗

Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype.Semantic proximity Read ↗

Fetal RHD genotyping is a cost-effective option for supporting targeted anti-D prophylaxis in D-negative pregnancies.Semantic proximity Read ↗

DEL variants: review of molecular mechanisms, clinical consequences and molecular testing strategy.Semantic proximity Read ↗

RHD genotyping to resolve weak and discrepant RhD patient phenotypes.Semantic proximity Read ↗

Transitioning a multiethnic donor pool from serologic D-negative to molecularly RHD-negative at a hospital-based blood donor service.Semantic proximity Read ↗

Guide to Rho(D) Immune Globulin in Women With Molecularly Defined Asian-type DEL (c.1227G>A).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.